1. Introduction {#sec1-ijms-20-01397}
===============

Despite promising advances in the understanding of molecular principles and in the treatment of leukemias, these neoplasms still present a substantial health problem in children and adults. Based on data collected in the United States of America from 2011 to 2015, the leukemia incidence rate is indicated with 13.8 new cases and 6.7 leukemia-associated deaths per 100,000 men and women per year ([seer.cancer.gov](seer.cancer.gov), accessed January 24, 2019). Leukemias are, in general, divisible into a chronic or acute disease type and based on the origin of the malignant cell population in myeloid or lymphoid lineage leading to the classification into four subtypes---chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). Beside these four subtypes there are a number of less common leukemia types, which are not covered in this review.

Within the four main subtypes, CML has a highly specific standard of care. The disease is characterized by the translocation t(9;22) that leads to the formation of the BCR-ABL fusion transcript \[[@B1-ijms-20-01397],[@B2-ijms-20-01397]\]. The resulting fusion protein mediates constitutive tyrosine kinase activity and drives the malignant transformation of CML cells \[[@B3-ijms-20-01397]\]. Inhibition of the BCR-ABL fusion protein by tyrosine kinase inhibitors (TKIs) has led to an impressive improvement in the prognosis of CML patients \[[@B4-ijms-20-01397],[@B5-ijms-20-01397],[@B6-ijms-20-01397]\]. This therapy can achieve a deep molecular response in which the discontinuation of the TKI can be considered; however, several patients suffer from a molecular relapse after a permanent stop of the TKI therapy \[[@B7-ijms-20-01397]\]. Therefore, the standard of care for CML patients includes lifelong TKI therapy, often associated with significant side effects and the risk of developing resistance to TKIs \[[@B8-ijms-20-01397],[@B9-ijms-20-01397]\]. In contrast to CML, the standard treatment for the acute leukemias AML and ALL is dominated by different combinations of chemotherapeutic agents as well as hematopoietic stem cell transplantation. Chemotherapies target in an unspecific manner dividing cells and initially achieve high remission rates; however, this is often followed by acquired drug resistances and high relapse rates especially in AML patients \[[@B10-ijms-20-01397],[@B11-ijms-20-01397]\]. As a result, there is a need for more specific post-remission therapies that are able to target residual chemoresistant malignant cells. In the case of CLL, the addition of CD20-targeting monoclonal antibodies (mABs), e.g., rituximab, to the standard chemotherapy with fludarabine and cyclophosphamide improved the progression-free and overall survival of CLL patients significantly \[[@B12-ijms-20-01397],[@B13-ijms-20-01397],[@B14-ijms-20-01397]\]. The combination of chemotherapy and anti-CD20 mABs comprises the current first-line of treatment for CLL patients after several decades of chemotherapy alone being the standard of care. This highlights the potential of targeted immunotherapies for the treatment of hematological malignancies to achieve long-term progression-free survival.

The immune system has the potential to cure cancers, as evident by the occurrence of spontaneous regression of cancers following infections and the graft-versus-leukemia effect after allogeneic stem cell transplantation in hematological malignancies \[[@B15-ijms-20-01397],[@B16-ijms-20-01397]\]. Immunotherapy is based on the (re)activation of the immune system to attack malignant cells. Non-specific immunotherapy approaches, such as allogeneic stem cell transplantation or interferon-α therapy, have shown to provide long-lasting responses in leukemia patients \[[@B17-ijms-20-01397],[@B18-ijms-20-01397]\]. Furthermore, immune checkpoint inhibitors, which have revolutionized the therapy of many solid tumors in recent years \[[@B19-ijms-20-01397],[@B20-ijms-20-01397],[@B21-ijms-20-01397],[@B22-ijms-20-01397],[@B23-ijms-20-01397],[@B24-ijms-20-01397]\], are currently being evaluated for the treatment of leukemias \[[@B25-ijms-20-01397],[@B26-ijms-20-01397]\]. However, checkpoint inhibitors led to an improved clinical outcome only in a subset of patients and cancer entities, and failed to achieve overall survival benefits in a number of studies \[[@B27-ijms-20-01397],[@B28-ijms-20-01397],[@B29-ijms-20-01397],[@B30-ijms-20-01397]\]. The mutational burden of the cancer and, in case of programmed death-1 (PD-1)-directed checkpoint inhibitors, the programmed death-ligand 1 (PD-L1) expression level on tumor cells have been linked to a favorable outcome of patients treated with checkpoint inhibitors \[[@B31-ijms-20-01397],[@B32-ijms-20-01397]\]. Therefore, further studies are necessary to identify relevant biomarkers in order to select patients, which could benefit from checkpoint inhibitor therapy. Furthermore, the evaluation of suitable combinations of checkpoint inhibitors with conventional chemotherapies, as already successfully proven for lung cancer \[[@B33-ijms-20-01397]\], or antigen-specific immunotherapies in a cancer entity-specific manner might be a promising approach to increase the number of patients that benefit from immune checkpoint inhibition.

Further advanced immunotherapeutic approaches include agents that induce a more specific immune response against malignant cells, such as vaccines, antibodies, or engineered T cells. The main prerequisite for the development of such antigen-based immunotherapy concepts is the identification of suitable target structures that are specifically expressed on malignant cells. In general, the targets for antigen-specific immunotherapies can be divided into two groups: (1) T-cell epitopes relying on the presentation of peptides via human leukocyte antigen (HLA) molecules and (2) surface structures, which are HLA-independently expressed on cancer cells ([Figure 1](#ijms-20-01397-f001){ref-type="fig"}). This review discusses the most promising tumor antigens for the further development of anti-leukemia immunotherapies.

2. HLA-Independent Antigens {#sec2-ijms-20-01397}
===========================

Immunotherapeutic approaches targeting HLA-independent antigens are restricted to molecules expressed on the surface of malignant cells. The advantage of these antigens is that they can be represented by any molecule on the cell surface; they are not restricted to peptides bound to an HLA molecule. However, the range of suitable HLA-independent antigens is limited as they have to be exclusively expressed on malignant cells or, if expressed also on benign tissue, at least on partially dispensable tissue to avoid on-target/off-tumor effects. In recent years, different immunotherapy approaches for leukemia, such as mABs, bispecific antibodies (bsABs), antibody-drug conjugates (ADCs), or chimeric antigen receptor (CAR) T cells, have been developed to target cell surface molecules \[[@B34-ijms-20-01397],[@B35-ijms-20-01397],[@B36-ijms-20-01397],[@B37-ijms-20-01397],[@B38-ijms-20-01397],[@B39-ijms-20-01397],[@B40-ijms-20-01397]\]. Such approaches rely on the specific binding to surface antigens. Several B cell-specific surface markers are described, which enable a variety of different immunotherapy approaches to target B-cell malignancies, including CLL and B-ALL. In contrast to these advances, suitable targets, especially for T cell-derived malignancies, are not available, preventing the development of effective targeted therapies so far. The need to identify novel antigens for immunotherapy also holds true for AML and CML patients, because surface molecules expressed on myeloid blasts can also be detected on normal myeloid cells, leaving only a few suitable membrane-expressed antigens that are safe to be targeted by immunotherapy approaches \[[@B41-ijms-20-01397]\].

In the following sections, the most promising antigens for HLA-independent immunotherapy approaches in leukemia are discussed in more detail. In addition to the described targets, there is a variety of other cell surface molecules currently being evaluated in clinical trials and preclinical tests to determine their suitability as targets for immunotherapies, including, for example, BAFF-R, CD23, CD64, CD133, CLL-1, ROR1, and the lambda or kappa light chain of the B-cell receptor (BCR) \[[@B42-ijms-20-01397],[@B43-ijms-20-01397],[@B44-ijms-20-01397],[@B45-ijms-20-01397],[@B46-ijms-20-01397],[@B47-ijms-20-01397],[@B48-ijms-20-01397]\].

2.1. CD19 {#sec2dot1-ijms-20-01397}
---------

CD19 is a surface molecule commonly expressed on B cells and is thereby a favorable target for B-cell malignancies, such as ALL and CLL. It was first described by Nadler et al. \[[@B49-ijms-20-01397]\], and acts as coreceptor for the B-cell antigen receptor complex. The bsAB blinatumomab and CAR T cells targeting CD19 showed very promising results in ALL and CLL. Both therapies are currently approved for anti-leukemia therapy in patients with ALL \[[@B50-ijms-20-01397],[@B51-ijms-20-01397],[@B52-ijms-20-01397]\]. CD19-directed CAR T cells could achieve complete remissions in up to 90% of patients with relapsed B-ALL \[[@B39-ijms-20-01397]\], whereas durable anti-tumor responses were observed in only 26% of CLL patients infused with CAR T cells targeting CD19 \[[@B50-ijms-20-01397]\]. The most common side effects of CD19-directed immunotherapies are the cytokine-release syndrome, manageable B-cell aplasia, due to the expression of CD19 also on benign B cells, and neurotoxicities in a subset of patients \[[@B51-ijms-20-01397],[@B53-ijms-20-01397]\]. A general problem of immunotherapies targeting a single antigen is epitope loss. In about 10% to 20% of ALL patients, a relapse of CD19-negative leukemic cells was reported after treatment with blinatumomab or CD19-specific CAR T cells \[[@B54-ijms-20-01397],[@B55-ijms-20-01397]\]. The optimal approach to overcome epitope loss is the combination of different antigen targets or therapies. Several combination therapies targeting CD19 together with another specific antigen, such as CD20 or CD22, are currently being evaluated in clinical trials yielding first promising results \[[@B40-ijms-20-01397],[@B56-ijms-20-01397]\].

2.2. CD20 and CD22 {#sec2dot2-ijms-20-01397}
------------------

CD20 and CD22 are both expressed on benign and malignant B cells and are suitable targets for the treatment of B-cell malignancies either as single treatment or as part of a combination therapy. Well-established immunotherapeutic agents in the treatment of CLL targeting CD20 are the humanized murine mABs rituximab and obinutuzumab \[[@B12-ijms-20-01397],[@B13-ijms-20-01397],[@B14-ijms-20-01397]\]. There are several approaches of combination therapies targeting CD19 and CD20 to prevent antigen loss. For example, CAR T cells expressing an anti-CD19/CD20 bispecific receptor, which prevented antigen escape of malignant B cells in lymphoma cell lines \[[@B40-ijms-20-01397]\].

CD22 is a sialoglycoprotein and part of the immunoglobulin superfamily. When CD22 is bound by a mAB it gets rapidly internalized, qualifying it as an excellent target for ADC-based immunotherapy \[[@B57-ijms-20-01397]\]. Inotuzumab ozogamicin, an ADC comprised of a humanized mAB against CD22 conjugated to the cytotoxic agent calicheamicin, led to a higher progression-free and overall survival in B-ALL patients compared to the standard therapy \[[@B58-ijms-20-01397]\]. CD22-targeting CAR T cells induced remissions in B-ALL patients that were either naïve or developed resistance to CD19-specific immunotherapy \[[@B59-ijms-20-01397]\]. Furthermore, the development of anti-CD19/CD22 bispecific CAR T cells showed first promising results in ALL cell line xenograft and patient-derived xenograft experiments \[[@B56-ijms-20-01397]\].

2.3. CD33 {#sec2dot3-ijms-20-01397}
---------

The CD33 antigen, also named sialic acid-binding Ig-like lectin 3 (Siglec-3), is expressed on the cell surface of myeloid cells and plays a role in mediating cell-cell interactions. This marker is expressed on AML blasts in up to 90% of the cases and on AML progenitor cells, but also on benign myeloid cells \[[@B60-ijms-20-01397],[@B61-ijms-20-01397]\]. This complicates targeting CD33 due to myelosuppression in patients treated with CD33-targeted immunotherapies \[[@B38-ijms-20-01397],[@B62-ijms-20-01397]\]. The ADC gemtuzumab ozogamicin was the first approved targeted compound for CD33. It was granted accelerated approval by the FDA in the year 2000 following a promising phase II study; however, a phase III study revealed considerable liver toxicity and the drug was voluntarily withdrawn after it failed to show a survival benefit compared to chemotherapy \[[@B63-ijms-20-01397]\]. In 2017, the FDA reapproved gemtuzumab ozogamicin for newly diagnosed and relapsed/refractory AML patients due to novel findings in clinical trials which applied different doses and different schedules of the drug \[[@B64-ijms-20-01397]\]. CAR T cells against CD33 displayed significant effector functions in vitro, but reduction of myeloid progenitors in xenograft models and one AML patient suggested that persistence of CD33-specific CAR T cells entails huge hematopoietic toxicity \[[@B62-ijms-20-01397],[@B65-ijms-20-01397]\]. In contrast, AMG 330, a CD3/CD33-targeting bsAB, showed promising preclinical data, suggesting it as a potential future therapy for AML \[[@B36-ijms-20-01397]\].

2.4. CD123 {#sec2dot4-ijms-20-01397}
----------

Interleukin-3 receptor subunit alpha or CD123 is very frequently expressed on both blast and leukemic progenitor cell populations in AML as well as in B-ALL and other rare leukemia subtypes, but not in T-ALL \[[@B66-ijms-20-01397]\]. Due to the important role of interleukin-3 signaling in hematopoietic development, CD123 is also present on hematopoietic stem/progenitor cells; however, in contrast to CD33, CD123 shows only low to negligible expression on corresponding benign cells \[[@B67-ijms-20-01397]\]. This differential expression pattern predefines CD123 as an attractive target. So far, immunotherapeutic approaches against CD123 revealed tolerable toxicity and promising anti-leukemia effects in preclinical and phase I studies \[[@B35-ijms-20-01397],[@B37-ijms-20-01397],[@B68-ijms-20-01397],[@B69-ijms-20-01397]\]. The combination of CD123- and CD19-directed CAR T cells could demonstrate an improved outcome in xenograft models and holds the potential to overcome CD19 epitope loss in B-ALL \[[@B70-ijms-20-01397]\].

2.5. FMS-Like Tyrosine Kinase-3 (FLT3) {#sec2dot5-ijms-20-01397}
--------------------------------------

The receptor tyrosine kinase FMS-like tyrosine kinase-3 (FLT3) plays an important role in the development of the hematopoietic and the immune system \[[@B71-ijms-20-01397]\]. FLT3 is expressed on the cell surface of AML blasts and approximately one-third of AML patients carry internal tandem duplications (ITDs) in the FLT3 gene, which are associated with a poor prognosis \[[@B72-ijms-20-01397]\]. The FLT3-ITD mutations lead to conformational changes of the receptor and thereby to constitutive autophosphorylation and induction of proliferation \[[@B73-ijms-20-01397]\]. This role in disease development underlines the potential of FLT3 as a suitable target in AML patients. Potent reactivity of CAR T cells targeting FLT3 was demonstrated against AML cell lines and primary AML blasts in mouse models \[[@B74-ijms-20-01397]\]. The mAB FLYSYN targeting mutated and unmutated FLT3 is currently being evaluated in a clinical study \[[@B34-ijms-20-01397]\]. Additionally, a bsAB targeting FLT3 and CD3 was developed on the basis of the FLYSYN mAB and exhibited enhanced cellular cytotoxicity against FLT3-expressing AML cells in comparison to the mAB alone \[[@B75-ijms-20-01397]\]. A combination of TKIs and the FLT3-targeting bsAB also revealed promising results, explained by an increased cell surface localization of FLT3-ITD after TKI treatment in xenograft models with blast cells from FLT3-ITD-positive AML patients \[[@B76-ijms-20-01397]\].

3. HLA-Dependent Antigens {#sec3-ijms-20-01397}
=========================

The presentation of peptides bound to HLA molecules on the surface of a cell comprises the core of the antigen presentation machinery of the immune system. The entirety of HLA-presented peptides is referred to as the immunopeptidome. HLA class I or class II molecules present peptides to CD8^+^ or CD4^+^ T cells, respectively, and can thereby trigger the eradication of malignant or infected cells. Leukemia-specific HLA epitopes can be exploited for immunotherapy approaches to induce anti-leukemia T-cell responses. One main advantage of the HLA-dependent presentation of antigens is that these antigens can also originate from intracellular proteins and are not restricted to surface proteins. Therefore, the number of potential targets is considerably higher, which facilitates the identification of new antigens. However, the HLA allotype restriction of the peptide targets represents a limitation concerning the development of broadly applicable immunotherapy approaches and calls for the combination of peptides of various HLA restrictions or for patient (group)-individualized approaches. Several strategies such as peptide, DNA/RNA, or dendritic cell (DC) vaccination approaches have been developed to target tumor-specific T-cell epitopes. These studies clearly showed that such vaccination approaches are able to induce T-cell responses and are furthermore well tolerated with only minor side effects \[[@B77-ijms-20-01397],[@B78-ijms-20-01397],[@B79-ijms-20-01397]\]. Moreover, HLA epitopes can also be targeted by specific antibodies or by adoptive T-cell transfer using T cells transduced with a known T-cell receptor (TCR) against a single tumor-associated antigen \[[@B80-ijms-20-01397],[@B81-ijms-20-01397]\].

3.1. Identification Methods {#sec3dot1-ijms-20-01397}
---------------------------

There are basically two different approaches for the identification of suitable HLA-restricted target antigens for immunotherapy---a gene expression-based so-called reverse immunology approach and an immunopeptidome-centric approach as illustrated in [Figure 2](#ijms-20-01397-f002){ref-type="fig"}. The reverse immunology approach focuses on genome/exome and/or RNA sequencing of malignant cells in comparison to a healthy control with the aim of identifying non-synonymous mutations or upregulated proteins, which are specific for the malignant cells. In order to determine potential HLA ligands derived from these mutated or upregulated proteins, an in silico prediction is performed followed by further validation steps and immunogenicity analyses of the predicted epitopes in T-cell assays \[[@B82-ijms-20-01397],[@B83-ijms-20-01397],[@B84-ijms-20-01397]\]. This method has several limitations for the identification of suitable targets for anti-leukemia immunotherapy. First, there is no direct correlation between the genome, the transcriptome, the proteome, and the naturally presented immunopeptidome \[[@B85-ijms-20-01397],[@B86-ijms-20-01397],[@B87-ijms-20-01397],[@B88-ijms-20-01397],[@B89-ijms-20-01397]\], thus making assumptions based solely on gene expression data inconclusive. Nevertheless, the gene expression-based approach plays an important role for the identification of tumor-specific mutated genes that could lead to the presentation of so-called neoantigens, which are known to play a major role in immune responses against cancers, especially in the context of immune checkpoint inhibitors \[[@B90-ijms-20-01397],[@B91-ijms-20-01397],[@B92-ijms-20-01397],[@B93-ijms-20-01397],[@B94-ijms-20-01397],[@B95-ijms-20-01397]\]. However, several studies provide evidence that only a very small fraction of the genomic mutations in a cancer cell is presented as HLA ligand on the cell surface \[[@B93-ijms-20-01397],[@B95-ijms-20-01397],[@B96-ijms-20-01397],[@B97-ijms-20-01397]\]. Exemplarily, a personalized vaccination study for newly diagnosed glioblastoma patients (*n* = 15) identified a total of 643 genomic mutations, but could confirm none of them in the HLA class I and II immunopeptidome of the corresponding patients \[[@B98-ijms-20-01397]\]. Another study searching for neoantigen-derived HLA ligands in melanoma patients, a cancer entity bearing one of the highest mutational burdens \[[@B91-ijms-20-01397]\], detected in five patients with a high number of non-synonymous mutations (\>15,000 per tumor sample) only 11 naturally presented neoepitopes \[[@B87-ijms-20-01397]\]. This data suggests a minor role of genome sequencing-based neoantigen predictions for the treatment of leukemias, which are known as low mutational burden malignancies \[[@B91-ijms-20-01397]\].

The immunopeptidome-centric approach focuses on the direct identification of naturally presented HLA-restricted peptides on malignant cells \[[@B99-ijms-20-01397]\]. Therefore, HLA-peptide complexes are isolated from lysed cells by immunoaffinity purification with HLA-specific antibodies and subsequently analyzed by liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) \[[@B86-ijms-20-01397],[@B100-ijms-20-01397],[@B101-ijms-20-01397],[@B102-ijms-20-01397],[@B103-ijms-20-01397],[@B104-ijms-20-01397],[@B105-ijms-20-01397],[@B106-ijms-20-01397]\]. To identify leukemia-exclusive HLA ligands, the immunopeptidomes of malignant cells and benign samples from healthy donors are comparatively analyzed. Exclusive or strongly upregulated ligands are then further analyzed in T-cell assays to determine their capacity to induce peptide-specific T-cell responses \[[@B101-ijms-20-01397],[@B104-ijms-20-01397],[@B107-ijms-20-01397]\]. Technological advances in recent years enable comprehensive mapping of the immunopeptidome landscape of primary patient material in unprecedented depth, which, in turn, allows for the implementation of novel strategies of antigen identification based solely on HLA ligandome data \[[@B87-ijms-20-01397],[@B98-ijms-20-01397],[@B101-ijms-20-01397],[@B103-ijms-20-01397],[@B104-ijms-20-01397],[@B108-ijms-20-01397]\]. This is, so far, the only unbiased methodology to comprehensively analyze the naturally presented HLA-peptide repertoire and might, therefore, represent a highly effective and indispensable method for the identification of immunologically relevant tumor antigens \[[@B109-ijms-20-01397]\].

3.2. HLA-Presented Peptide Targets {#sec3dot2-ijms-20-01397}
----------------------------------

In recent years, a considerable number of leukemia-associated antigens (LAAs) have been described and will be discussed in detail in the following subsections. Several of these LAAs showed promising results in preclinical and clinical studies for their use in immunotherapy approaches. An overview of currently ongoing clinical studies based on HLA-presented peptide targets in leukemia patients is set out in [Table 1](#ijms-20-01397-t001){ref-type="table"}. An important point, which must be considered, concerning the selection of HLA-presented LAAs, is that tumor-exclusivity can either be assessed on the level of HLA ligands or on the level of the entire antigen. Single HLA ligands from one protein can be tumor-exclusive even if other peptides from the same antigen are also presented on benign cells. This fact could be explained by different splicing, protein modifications, or antigen processing in cancer cells, which lead to an altered presentation of the immunopeptidome compared to benign cells \[[@B104-ijms-20-01397]\]. Therefore, the Tübingen approach was developed to identify immunotherapeutic relevant HLA ligands. In a first step, naturally presented HLA-restricted peptides are directly identified from primary tumor cells using the LC-MS/MS technology. Next, identified tumor-associated peptides are selected by differential gene expression analysis, data mining, and most importantly, comparative analysis with the ligandome of benign cells. In a last step, selected candidates are validated by in vitro T-cell assays and, where possible, monitoring in vivo T-cell responses in the context of patient-individualized immunizations \[[@B110-ijms-20-01397]\]. Studies following this approach allow, on the one hand, the development of broadly applicable off-the-shelf immunotherapies targeting non-mutated LAAs, especially for malignancies with low mutational burden including leukemias \[[@B86-ijms-20-01397],[@B104-ijms-20-01397],[@B108-ijms-20-01397]\], and on the other hand, the design of personalized peptide-based immunotherapies based on the patient-individual immunopeptidome analysis of tumor cells \[[@B111-ijms-20-01397]\]. A recently conducted meta-analysis of the HLA peptidome composition in different hematological entities revealed that there is only a small amount of entity-spanning antigens, suggesting that the design of peptide-based immunotherapies for the treatment of hematological malignancies should ideally be realized in an entity-specific manner \[[@B112-ijms-20-01397]\].

The following subsections provide insights into the most promising antigen targets for novel immunotherapy approaches targeting leukemic cells in an HLA-dependent manner.

### 3.2.1. Wilms' Tumor Gene (WT1) {#sec3dot2dot1-ijms-20-01397}

Wilms' tumor gene (WT1) encodes a transcription factor, which was originally identified as mutated in patients with Wilms' tumor, a nephroblastoma that typically occurs in children. WT1 was described early as widely expressed in AML, ALL, and CML, but not in CLL \[[@B113-ijms-20-01397]\]. Expression of WT1 on normal hematopoietic progenitor cells was reported as at least 10 times less than in AML cells, confirming the overexpression of the WT1 gene in leukemic cells \[[@B114-ijms-20-01397]\]. Quantification of WT1 gene expression can be used to predict the probability of relapse and to detect minimal residual disease in AML patients \[[@B115-ijms-20-01397],[@B116-ijms-20-01397]\]. Interestingly, WT1 was ranked as the top immunotherapy target in cancer by a national cancer institute pilot project for the prioritization of cancer antigens \[[@B117-ijms-20-01397]\]. Numerous clinical studies were carried out implementing peptide vaccination strategies for AML patients in remission after an initial chemotherapy and demonstrated that they are able to induce T-cell responses and are well tolerated with only minor side effects \[[@B79-ijms-20-01397],[@B118-ijms-20-01397],[@B119-ijms-20-01397],[@B120-ijms-20-01397]\]. Furthermore, DC vaccination and adoptive transfer of WT1-specific cytotoxic T cells showed to be auspicious therapeutic options in combination with allogeneic stem cell transplantation in AML patients \[[@B121-ijms-20-01397],[@B122-ijms-20-01397]\].

### 3.2.2. Telomerase {#sec3dot2dot2-ijms-20-01397}

One of the most important proteins for cancer development and progression, also titled the "universal tumor-associated antigen", the human telomerase reverse transcriptase (hTERT) is up-regulated or reactivated in approximately 90% of human cancers \[[@B123-ijms-20-01397]\]. In healthy individuals, hTERT maintains telomere length in stem and germ cells but is usually silenced in almost all somatic cells. The first identified immunogenic peptide from hTERT was I540 (ILAKFLHWL) restricted to HLA-A\*02 \[[@B124-ijms-20-01397]\]. Since then, several peptides of hTERT have been described as immunogenic and increasing evidence suggests that the protein can serve as a suitable target for widely applicable immunotherapy approaches against cancer. A DC vaccination study targeting hTERT induced in 11 out of 19 AML patients hTERT-specific T-cell responses and 64% of the responders were free of disease recurrence at the time of their last follow-up with a median follow-up of 52 months \[[@B125-ijms-20-01397]\]. In humanized mouse models, adoptive T-cell transfer utilizing T cells transduced with a TCR recognizing an HLA-A\*02-restricted hTERT-derived peptide were able to control human B-ALL, CLL, as well as AML progression in vivo, supporting the feasibility of hTERT-directed adoptive immunotherapy \[[@B126-ijms-20-01397],[@B127-ijms-20-01397]\].

### 3.2.3. Receptor for Hyaluronan-Mediated Motility (RHAMM) {#sec3dot2dot3-ijms-20-01397}

CD168 or receptor for hyaluronan-mediated motility (RHAMM) was described as widely expressed LAA in AML, CML, and CLL \[[@B128-ijms-20-01397],[@B129-ijms-20-01397]\]. A possible role of RHAMM as a biomarker for patient prognosis in acute pediatric leukemias was investigated revealing that patients with a high percentage of RHAMM-positive blast cells at the time of diagnosis had more blasts in minimal residual disease and a poorer prognosis \[[@B130-ijms-20-01397]\]. By the in silico prediction of potential HLA-A\*02-presented peptides from RHAMM, the peptide R3 (ILSLELMKL) was first characterized as a highly immunogenic CD8^+^ T-cell epitope in AML patients \[[@B83-ijms-20-01397]\]. A phase I clinical trial assessed the efficacy of a peptide vaccination with RHAMM R3 in patients with AML, myelodysplastic syndrome (MDS), and multiple myeloma and showed in 7 out of 10 patients an increase of RHAMM R3-specific effector T cells with three patients achieving clinical responses \[[@B131-ijms-20-01397]\]. Another study with RHAMM R3 was conducted in six CLL patients and showed similar promising results \[[@B132-ijms-20-01397]\]. Interestingly, it was described that RHAMM is already expressed and presented by monocyte-derived DCs from AML patients in a DC vaccination setting, even without RHAMM mRNA electroporation, and that this is sufficient to activate RHAMM-specific T cells \[[@B133-ijms-20-01397]\]. On the contrary, a study by Schauwaert et al. concluded that RHAMM is a suboptimal target antigen for immunotherapy approaches in AML patients, due to an equal expression level of RHAMM in leukemic stem cells and hematopoietic stem cells from healthy controls indicating that an elimination of leukemic stem cells is unlikely to be achieved by RHAMM-directed immunotherapy \[[@B134-ijms-20-01397]\].

### 3.2.4. Preferentially Expressed Antigen of Melanoma (PRAME) {#sec3dot2dot4-ijms-20-01397}

The antigen PRAME (preferentially expressed antigen of melanoma) was initially identified in two melanoma cell lines and was described to be overexpressed in a large fraction of different tumors and leukemias. PRAME is a classical cancer-testis antigen and is considered a highly attractive target in leukemias. Multiple HLA-A\*02-restricted epitopes of PRAME e.g., VLDGLDVLL, SLYSFPEPEA, ALYVDSLFFL, and SLLQHLIGL have been described and showed spontaneous CD8^+^ T-cell reactivity in ALL, AML, and CML patients \[[@B135-ijms-20-01397]\]. The ALYVDSLFFL/HLA-A\*02 complex can also be targeted by the TCR mimic mAB Pr20, which was therapeutically effective in mouse xenograft models of human leukemias \[[@B136-ijms-20-01397]\]. Another study identified PRAME peptide-specific CD8^+^ effector and effector memory T cells in healthy individuals, which suggests PRAME as the preferable LAA for adoptive T-cell therapies focusing on the generation of LAA-specific T cells from healthy allogeneic HLA-matched T-cell donors \[[@B137-ijms-20-01397]\].

### 3.2.5. PR1 {#sec3dot2dot5-ijms-20-01397}

The PR1 epitope is a nonameric peptide (VLQELNVTV) in complex with an HLA-A\*02 molecule and is recognized by cytotoxic T lymphocytes when it is presented on the surface of CML or AML cells in patients. It originates from the two serine proteases proteinase 3 (P3) and neutrophil elastase (NE) that are overexpressed and mislocalized in myeloid leukemia blasts \[[@B138-ijms-20-01397]\]. A peptide vaccination study, including 66 patients with CML, MDS, or AML, showed that PR1 induced specific immunity correlated with clinical responses, including molecular remission \[[@B139-ijms-20-01397]\]. Furthermore, the novel developed T-cell receptor-like mAB 8F4 binds with high affinity a combined epitope of the PR1/HLA-A\*02 complex and induced complement-dependent cytolysis of AML blasts and Lin^−^CD34^+^CD38^−^ leukemic stem cells, but not of normal leukocytes \[[@B140-ijms-20-01397]\]. The Molldrem group also developed a bsAB binding the PR1/HLA-A\*02 complex and CD3 to improve the potency of the 8F4 mAB. This bsAB could activate T cells to lyse HLA-A\*02^+^ primary AML blasts and cell lines \[[@B141-ijms-20-01397]\]. Additionally, a TCR-like CAR with specificity for the PR1/HLA-A\*02 complex, on the basis of the 8F4 mAB, was constructed, and transduced CAR T cells were capable to kill leukemia cell lines and primary AML blasts in vitro in an HLA-A\*02-dependent manner \[[@B142-ijms-20-01397]\].

### 3.2.6. Survivin {#sec3dot2dot6-ijms-20-01397}

The survivin protein, also known as baculoviral IAP repeat-containing protein 5 (BIRC5), is an inhibitor of apoptosis and promotes cell survival. Survivin gene expression was proven in ALL, AML, and CML blasts, but not in normal bone marrow cells. Additionally, the disease-free survival rates of patients with survivin expression were lower than that of patients without survivin expression \[[@B143-ijms-20-01397]\]. In a proof of concept study, using a xenograft mouse model of primary ALL, the knockdown of survivin by shRNA in combination with chemotherapy resulted in no detectable minimal residual disease, demonstrating that targeting survivin can overcome chemotherapy resistance \[[@B144-ijms-20-01397]\]. In an expression analysis effort of adult B-ALL patients, survivin was the only LAA that was identified to be significantly overexpressed in these patients compared to healthy donor samples, suggesting survivin as an excellent target antigen for immunotherapy in adult B-ALL patients \[[@B145-ijms-20-01397]\].

### 3.2.7. BCR-ABL {#sec3dot2dot7-ijms-20-01397}

Philadelphia-positive leukemias, including CML and some ALL cases, possess the BCR-ABL fusion protein, which originates from the chromosome translocation t(9;22). This translocation results in novel BCR-ABL fusion regions and peptides originating from these breakpoints can be classified as leukemia-specific neoantigens. Therefore, the BCR-ABL fusion region is an attractive leukemia-specific T-cell target. Furthermore, most patients with a Philadelphia-positive leukemia receive TKI therapy, which can lead to additional mutations in the BCR-ABL fusion protein in order to achieve resistance to the inhibitor, which in turn could lead to new neoantigens naturally presented on the cell surface. By the use of epitope prediction, several immunogenic BCR-ABL fusion region peptides were described, which could induce BCR-ABL-specific CD4^+^ and CD8^+^ T-cell responses \[[@B146-ijms-20-01397],[@B147-ijms-20-01397],[@B148-ijms-20-01397]\]. These T cells were capable of controlling treatment-refractory Philadelphia-positive ALL in vivo after adoptive T-cell therapy \[[@B146-ijms-20-01397]\]. An in vitro study, which computationally predicted new TKI therapy-induced BCR-ABL neoantigens, could demonstrate specific CD8^+^ T cells against a HLA-A\*03-restricted peptide in the blood of two CML patients \[[@B149-ijms-20-01397]\]. The BCR-ABL-specific HLA-A\*03-restricted peptide KQSSKALQR was reported as identified in one patient by LC-MS/MS \[[@B150-ijms-20-01397]\]. However, a recent study searching for BCR-ABL- and ABL-BCR-derived neoepitopes in 21 CML patients, including eight HLA-A\*03-positive patients, could not detect any naturally presented neoepitopes by LC-MS/MS analysis \[[@B104-ijms-20-01397]\]. This indicates that these epitopes are rare and technically challenging to confirm.

### 3.2.8. NPM1 {#sec3dot2dot8-ijms-20-01397}

C-terminal mutation in nucleophosmin (NPM1) defines the most frequent mutation in AML and is associated with a favorable prognosis of patients \[[@B151-ijms-20-01397]\]. This beneficial outcome of NPM1-mutated AMLs is linked to the recognition of the NMP1 mutation by the immune system leading to CD4^+^ and CD8^+^ T-cell responses in patients \[[@B152-ijms-20-01397],[@B153-ijms-20-01397]\]. Furthermore, an association of HLA class I genotypes with the prevalence and outcome of patients with AML and mutated NPM1 was reported, indicating the importance of peptide presentation on certain HLA molecules \[[@B154-ijms-20-01397]\]. In a recent study, researchers isolated CD8^+^ T cells recognizing the LC-MS/MS-validated HLA-A\*02-restricted neoepitope CLAVEEVSL \[[@B155-ijms-20-01397]\]. Additionally, they isolated the epitope-specific TCR and demonstrated in a xenograft model the capacity of TCR-transduced T cells to lyse AML cells expressing mutated NPM1. All these findings suggest NPM1 as an excellent target antigen for HLA-dependent immunotherapy approaches in AML patients with NPM1 mutations.

4. Conclusions {#sec4-ijms-20-01397}
==============

Antigen-specific immunotherapy is a rapidly growing field providing promising new therapeutic options in virtually all areas of cancer therapy, including leukemias. Checkpoint inhibitors, monoclonal and bispecific ABs, adoptive T-cell transfer, and vaccination approaches hold the potential to improve the prognosis and survival of leukemia patients. To further increase the number of patients that benefit from antigen-specific immunotherapies, the characterization of suitable target antigens, fulfilling the following criteria, is indispensable: (1) Tumor exclusivity, the antigen should be naturally presented and only expressed on malignant cells to minimize on-target/off-tumor effects in patients; (2) immunogenicity, the naturally presented epitope should be recognized by T cells in vivo; (3) broad expression, the optimal target should be highly expressed in a majority of patients or even spanning several cancer entities.

HLA-independent targets exhibit the advantage that they are broadly applicable for many patients due to lineage-specific expression patterns, but the variety of possible antigens that are exclusively expressed on cancer cells is limited. In contrast, there is a large variety of tumor antigens presented by HLA molecules with the limitation of the restriction to a specific HLA allotype. However, a single optimal tumor antigen for all cancer entities might not exist. Targeting several antigens seems beneficial in terms of increasing specificity and minimizing the possibility of antigen loss and therapy resistance of malignant cells. Therefore, a combination of antigens and targeting modalities might be the future for clinically effective cancer immunotherapy. This includes, for example, the combination of antigen-specific therapies with unspecific therapies such as immune checkpoint inhibitors or cytokines for the achievement of synergistic effects from various immunotherapeutic agents \[[@B93-ijms-20-01397],[@B156-ijms-20-01397],[@B157-ijms-20-01397]\]. Moreover, the optimal combination of immunotherapies, especially vaccination-based approaches, with suitable adjuvants, including, for example, Toll-like receptor (TLR) agonists \[[@B158-ijms-20-01397],[@B159-ijms-20-01397]\], has to be further evaluated in order to boost the efficacy of cancer immunotherapies \[[@B160-ijms-20-01397]\]. Over the last decade, the methodology for antigen detection, as well as for effective targeting of tumor antigens, has experienced a quantum leap, providing us all necessary tools required for an effective anti-leukemia immunotherapy. Future studies are now facing the challenging task to select and combine these antigens and immunotherapeutic approaches to design an effective treatment for each individual leukemia patient.
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ADC

Antibody-drug conjugate

ALL

Acute lymphoblastic leukemia

AML

Acute myeloid leukemia

BCR

B-cell receptor

bsAB

Bispecific antibody

CAR

Chimeric antigen receptor

CLL

Chronic lymphocytic leukemia

CML

Chronic myeloid leukemia

DC

Dendritic cell

FLT3

FMS-like tyrosine kinase-3

HLA

Human leukocyte antigen

hTERT

Human telomerase reverse transcriptase

ITD

Internal tandem duplication

LAA

Leukemia-associated antigen

LC-MS/MS

Liquid chromatography-coupled tandem mass spectrometry

mAB

Monoclonal antibody

MDS

Myelodysplastic syndrome

NPM1

Nucleophosmin

PRAME

Preferentially expressed antigen of melanoma

PD-1

Programmed death-1

PD-L1

Programmed death-ligand 1

RHAMM

Receptor for hyaluronan-mediated motility

TCR

T-cell receptor

TLR

Toll-like receptor

TKI

Tyrosine kinase inhibitor

WT1

Wilms' tumor gene

![Schematic overview of human leukocyte antigen (HLA)-independent and HLA-dependent antigen-specific cancer immunotherapy approaches. The HLA-independent approach focusses on antibody-based technologies targeting surface structures via e.g., monoclonal antibodies (mABs), bispecific antibodies (bsABs), chimeric antigen receptor (CAR) T cells, or antibody-drug conjugates (ADCs). HLA-dependent immunotherapies induce peptide-specific immune responses mainly by peptide-, RNA/DNA-, or dendritic cell (DC)-based vaccines, and adoptive transfer of activated or T-cell receptor-transduced T cells.](ijms-20-01397-g001){#ijms-20-01397-f001}

![Schematic overview of the immunopeptidome-centric approach and the gene expression-based reverse immunology approach for the identification of HLA-presented peptides as targets for anti-cancer immunotherapy. A simplified depiction of the cellular processes involved in HLA antigen processing is illustrated, including (1) DNA transcription, (2) protein biosynthesis, (3) proteasomal degradation, and (4) peptide loading on HLA molecules via the endoplasmic reticulum and the Golgi apparatus, resulting in (5) the cell surface presentation of the HLA-peptide complex. The direct identification of naturally presented HLA-restricted peptides is based on the isolation of HLA-peptide complexes, followed by peptide purification, and peptide sequence identification by liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS). In contrast, the reverse immunology approach is based on DNA and/or RNA isolation and sequencing, followed by in silico epitope prediction of mutation-derived or overexpressed proteins.](ijms-20-01397-g002){#ijms-20-01397-f002}
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###### 

Current clinical trials focusing on HLA-dependent immunotherapy in leukemia.

  -------------------------------------------------------------------------------------------------------------------------------------
  Identifier    Treatment                  Target                           Disease                    Phase   Status
  ------------- -------------------------- -------------------------------- -------------------------- ------- ------------------------
  NCT03083054   DC vaccination             WT1                              AML, MDS                   I/II    recruiting

  NCT02405338   DC vaccination             WT1, PRAME                       AML                        I/II    active, not recruiting

  NCT02543749   DC vaccination             BCR-ABL, WT1, PR3                CML                        I/II    recruiting

  NCT01686334   DC vaccination             WT1                              AML                        II      recruiting

  NCT03291444   DC vaccination\            WT1, Eps8                        ALL, AML, MDS              I       recruiting
                + CAR T cells                                                                                  

  NCT03265717   DNA vaccination            hTERT                            CLL                        II      recruiting

  NCT02802943   peptide vaccination        patient-individualized           CLL                        II      recruiting

  NCT03559413   peptide vaccination        patient-individualized           ALL                        I/II    recruiting

  NCT02750995   peptide vaccination\       NY-ESO-1, PRAME, MAGE-A3, WT1    AML, MDS                   I       recruiting
                + azacitidine                                                                                  

  NCT02494167   adoptive T-cell transfer   WT1, NY-ESO-1, PRAME, Survivin   AML, MDS                   I       recruiting

  NCT02475707   adoptive T-cell transfer   WT1, PRAME, Survivin             ALL                        I       recruiting

  NCT00620633   adoptive T-cell transfer   WT1                              leukemia, MDS              I       active, not recruiting

  NCT03326921   TCR-transduced\            HA-1                             ALL, AML                   I       recruiting
                adoptive T-cell transfer                                                                       

  NCT02770820   TCR-transduced\            WT1                              AML                        I/II    recruiting
                adoptive T-cell transfer                                                                       

  NCT02743611   TCR-transduced\            PRAME                            AML, MDS, uveal melanoma   I/II    recruiting
                adoptive T-cell transfer                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------
